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Abstract Blood flukes of the genus Schistosoma currently
infect millions of people in tropical and subtropical countries.
An enzyme playing a major role in hemoglobin (Hb) degrada-
tion by Schistosoma mansoni has been cloned and shown to be
highly similar to the human cathepsin D aspartyl proteinase,
although presenting a distinct substrate specificity from the
latter. Investigating the structural features responsible for this
difference has a major application in the design of selective anti-
schistosomal drugs. In order to achieve this goal a homology
model for the S. mansoni aspartyl hemoglobinase was
constructed and then used to simulate the complexes formed
with two transition state analogues of Hb-derived octapeptide
substrates. Comparison with human cathepsin D showed that
different pocket volumes and surface electrostatic potentials
arise from substitutions in residues comprising the S4, S3, S2
and S3P subsites. Since the primary specificity of the S. mansoni
enzyme resembles that of HIV-1 protease, we have discussed the
applicability of current retroviral protease inhibitors as leads for
the design of new anti-schistosomal drugs. ß 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Schistosomiasis is a major human parasitic disease. An es-
timative from the World Health Organization in 1993 [1] in-
dicates that the blood £ukes of the genus Schistosoma may
infect over 200 million people in more than 74 countries
throughout the world. Schistosome infestation is currently
both treatable and preventable. The former is being achieved
by oral administration of praziquantel or oxamniquine and
the later by health educational programs. Nevertheless, there
is no apparent sign of improvement in schistosomiasis mor-
bidity indexes in most developing countries, possibly due to a
premature increased tolerance to praziquantel [2]. Thus, seek-
ing novel strategies for schistosomiasis chemotherapy is of
major importance.
Schistosomes as any other blood-feeding parasite depend
on hemoglobin (Hb) catabolism for survival. Several already
characterized or putative Hb degrading enzymes have been
isolated from protozoans and helminths, including: Plasmo-
dium sp. [3^6], Ancylostoma caninum [7], Strongyloides sterco-
ralis [8] and Haemonchus contortus [9]. These proteolytic en-
zymes have been shown to belong either to the cysteinyl or to
the aspartyl families of peptidases [10]. In schistosomes, a
cathepsin D-like proteinase from both Schistosoma mansoni
and Schistosoma japonicum species has been cloned [11,12].
Human cathepsin D is an aspartyl protease that has been
assumed to be involved in the generation of peptides for anti-
gen presentation [13], cancer metastasis [14] as well as in the
formation of the plaques encountered in the Alzheimer’s dis-
ease [15]. Today, a lot of knowledge has been accumulated
from structural studies of aspartyl proteinases involved in the
pathogeny of important human diseases [16]. Nevertheless,
where no experimental information on the structure of the
studied protease is available, molecular modelling plays a cru-
cial role on the prediction of structure^function relationships
[17^20]. The value of these computational techniques has been
proved by the subsequent con¢rmation of numerous predic-
tions through comparison with the structures resolved by nu-
clear magnetic resonance techniques or, in a greater extent, by
X-ray crystallography [21^23].
Brindley et al. [24] have shown that the S. mansoni enzyme
presents a discrete substrate preference from its orthologous
host enzyme, cleaving human Hb in several distinct sites.
Therefore, exploring this di¡erence has a potential application
on the design of selective inhibitors of S. mansoni cathepsin
D-like hemoglobinase, which can represent a novel strategy
for the combat of schistosomiasis. Noticeably, Brinkworth et
al. [25] have recently focused the structural features responsi-
ble for the K-chain Phe36^Pro37 cleavage site on human Hb.
This is a very unusual site for an eukaryotic aspartyl protein-
ase since it was essentially only observed in the aspartyl pro-
teases of retroviral origin [16]. Pursuing the Phe^Pro cleavage
site is a very interesting approach for substrate-based inhibitor
design because it can furnish selectivity over eukaryotic en-
zymes. Nevertheless, addressing the general topological, elec-
trostatic and steric features responsible for the discrete sub-
strate preference shown by the schistosome and human
enzymes should be of greater interest for broad-spectrum
projects in structure-based drug design. Following this ap-
proach, a homology model for the S. mansoni aspartyl hemo-
globinase has been constructed and used to simulate the
complexes formed with two transition state analogues of
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Hb-derived octapeptide substrates (KL105^L106/SHCL*
LVTL and LL31^L32/LGRL*LVVY). The modelled com-
plexes were used to pinpoint the structural discrepancies
found in the subsites of the schistosome and human cathepsin
D enzymes that could be correlated to the enzymatic activities
and binding a⁄nities reported in the literature for these pro-
teases. In addition, in view of the similarity at the substrate
preference level of the aspartyl proteases of schistosoma and
HIV-1, we have discussed the feasibility of current HIV-1
protease inhibitors as leads for the design of novel anti-schis-
tosomal drugs.
2. Materials and methods
2.1. Sequence analysis
The sequence of the mature S. mansoni cathepsin D-like protease
(CatD_Sman), comprising 377 residues, was extracted from the zymo-
gen sequence deposited in TrEMBL protein databank under accession
number P91802. Aspartyl proteases found on the complexes of ca-
thepsin D-pepstatin (PDB ID 1LYB, 2.50 Aî resolution) [21], mouse
renin^CH-66 (PDB ID 1SMR, 2.00 Aî resolution) [22] and pepsin 3A-
phosphonate inhibitor (PDB ID 1QRP, 1.96 Aî resolution) [26] were
used as templates in the modelling procedure. A reliable alignment
between CatD_Sman and its templates was achieved by adjusting the
multiple sequence alignments obtained either from the pepsin A1
family in MEROPS database [27] or from ClustalW v. 1.72 [28], in
order to maximize the placement of insertions and deletions in loops
and to align features conserved in the pepsin family of proteases, such
as the three pairs of cysteine residues. This alignment was also used as
an input to the program MEGA v. 2.1 [29] to calculate the pairwise
distances (using the Poisson correction model and a pairwise deletion
of gap containing segments), which were used to generate a pheno-
gram by the neighbor-joining method. The reliability of each internal
branch was assessed by the bootstrap method implemented in MEGA.
2.2. Comparative molecular modelling
The sequence of CatD_Sman was folded onto the superposed struc-
tures of its templates according to the optimal alignment, obtained as
explained above, using the SwissPDB Viewer v. 3.6 program and then
submitted in optimize mode to the Swiss-Model automated modelling
server [30]. This modelling method has been rigorously assessed by a
large-scale initiative called the 3DCrunch project (http://www.expasy.
ch/swissmod/SM_3DCrunch.html). Brie£y, models whose sequences
shared around 50% identity to templates deviate from experimental
structures by approximately 1 Aî relative mean square deviation in the
common core. Suitability of the modelled CatD_Sman three dimen-
sional (3D) structure for this study was assessed with the analytical
tools available in SwissPDB Viewer v. 3.6 and with the programs in
the PROCHECK suite [31]. Residues corresponding to the carboxy-
terminal extension found in S. mansoni aspartyl protease were not
considered in the modelling because this segment showed to have
no counterpart on protein structures determined to date. As no func-
tion has been assigned to this region yet and as schistosomes are
believed to express both forms of the enzyme, with and without this
segment [11], we decided not to address this question here.
2.3. Modelling of active site residues
The geometry of the residues composing the catalytic triad in the
active site is highly conserved among the aspartyl proteases [16]. Fol-
lowing this principle, we have applied a manual torsion on the M2
angle of D33 and D219 side chains, taking as a guide the catalytic
aspartate side chains from human cathepsin D structure [21], in order
to guarantee that both groups belong to the plane observed in aspar-
tyl proteinases. Finally, 20 cycles of steepest descent and 20 cycles of
conjugate gradient energy minimization with the Gromos96 force ¢eld
[32] implemented in SwissPDB Viewer v. 3.6 were applied to release
any problems with stereochemistry that would have been imposed by
the manual torsion procedure.
2.4. Substrate modelling
The 3D structure of mouse renin complexed with the decapeptide
inhibitor CH-66 was used as the archetype to model the transition
state isoster of the pseudo-substrates LGRLi[CH(OH)CH2]LVVY
and SHCLi[CH(OH)CH2]LVYL. CH-66 was chosen because: (i) it
almost perfectly resembles the transition state intermediate formed
during the cleavage of a peptide bond and (ii) it would be large
enough to furnish the extended backbone necessary to model an oc-
tapeptide. Substrate modelling was achieved by superimposing the
CatD_Sman model on the enzyme^inhibitor complex of mouse renin
(0.70 Aî in 1264 backbone atoms) and then transferring the coordi-
nates of the inhibitor onto the model structure. Finally, collisions and
improper stereochemistry of the mutated side chains in the inhibitor^
enzyme complex were released by 20 cycles of steepest descent and 20
cycles of conjugate gradient energy minimization with the Gromos96
force ¢eld. Hydrogen bonds and non-bonded contacts between the
modelled transition state isosteres of Hb-derived substrates and
CatD_Sman model were calculated with HBPLUS [33].
3. Results and discussion
3.1. Overall model structure and validation
The structure of CatD_Sman, as expected, resembles that of
most eukaryotic aspartyl proteinases (Fig. 2A). A six-stranded
Fig. 1. Multiple sequence alignment used on the construction of
S. mansoni aspartyl hemoglobinase model. CatD_Sman ^ S. mansoni
aspartyl hemoglobinase; 1SMRA ^ mouse renin; 1LYB ^ human
cathepsin D and 1QRPE ^ human pepsin 3A. The black arrowhead
indicates the end of cathepsin D light chain. Asterisks in 1LYB se-
quence correspond to residues excised during post-translational pro-
cessing of human cathepsin D. The three conserved cysteine pairs
are highlighted in gray while the two catalytic triads are highlighted
in black. In the bottom of each alignment block is represented the
secondary structure of CatD_Sman derived from its model (coded
to facilitate discussion in the text). Secondary structure elements are
represented as cylinders (K-helices) and arrows (L-strands). The ¢rst
two residues in the CatD_Sman sequence (shown in grayish) were
not modelled neither considered in the numeration.
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L-sheet connects the two lobes of the protein and constitutes
the active site £oor. The catalytic apparatus is assembled in
the middle of the protease by two loops localized on the tips
of structures known as the ‘greek keys’ for their similarity to
the psi (i) [16]. Each of these loops contributes with three
residues Asp, Thr and Gly (D33, T34, G35 and D219,
T220, G221 according to the numeration used in Fig. 1)
that are highly conserved among the aspartyl proteases [16].
The L-turn positioned over the active site cleft, known as the
‘£ap’, is composed of residues H77, Y78, G79 and T80, in the
proposed model. The CatD_Sman sequence does not present
the insertion between residues L94 and G95, where would be
encountered the surface loop that is excised from human ca-
thepsin D (residues S98^L105, shown as asterisks in Fig. 1)
resulting in the formation of the light and heavy chains of this
enzyme. In the CatD_Sman model this loop was predicted as
a short L-turn between the s6N and s7N L-strands based on the
structures of mouse renin and human pepsin 3A.
Most uncertainties related to the CatD_Sman model were
identi¢ed in structurally variable regions (SVRs), as indicated
by the red-colored loops in Fig. 2A. Surprisingly, only two
disul¢de linkages could be detected in the model (represented
by the yellow lines connecting C46 to C53 and C253 to C290
in Fig. 3). The CatD_Sman model cannot assure the absence
of the linkage that would be formed by residues C210 and
C214 since the former is located in a SVR. The PROCHECK
suite of programs was used to assess the stereochemical qual-
ity of the model. Around 86% of the residues were plotted in
the most favored regions (A, B, L) of the Ramachandran plot.
Similar values were encountered on the analysis of the tem-
plates used in CatD_Sman modelling. Six residues (2.2%) felt
in generously allowed regions of the plot (S96, S98, V99, I163,
A164 and T305) and only four residues (1.4%) were found to
be in disallowed regions (N161, S163, S205 and K284). None
of these is found in CatD_Sman subsite pockets. On the main-
chain parameters check, the g angle standard deviation
showed to be 1.9 times above the typical value for high-reso-
lution structures. This angle, in general terms, represents a
measure of the peptide bond planarity. Residues with irregu-
lar g torsions that are near the substrate binding groove are
F32, L113 and M224. Remaining stereochemical parameters
Fig. 2. A: S. mansoni aspartyl hemoglobinase structure colored by model B-factor. Cold residues are shown in blue while hot residues are in
red. Labelled cysteine residues are shown as CPK-colored sticks. Disul¢de linkages are shown in yellow. B: Modelled complex between the
Hb-derived peptide KL105^L106 and CatD_Sman model. Top view of the active site binding groove where the surface was made transparent
to allow the perception of the internal protease architecture, depicted as greenish ribbons. The molecular surfaces in this work were calculated
in SwissPDB Viewer v. 1.6 [30] and colored according to the coulombic electrostatic potential: red ^ negative, blue ^ positive and white ^ neu-
tral.
Fig. 3. Phenogram of 54 mature sequences of representative aspartyl
proteinases (pepsin A1 family [27]) rooted with the HIV-1 protein-
ase monomer. The sequences were aligned using the ClustalW v.
1.81 program [28]. The tree was constructed according to the neigh-
bor-joining method from the calculated pairwise distances (MEGA
v. 2.1 [29]). Numbers on the branches represent percent agreement
values obtained by the bootstrap procedure. Sequences are denoted
with database accession numbers (tr: translated EMBL; sp: Swiss-
Prot) followed by codes in SwissProt format.
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for the whole CatD_Sman model were inside the expected
values.
3.2. Subsite speci¢city and comparison with human cathepsin D
active site
Brindley et al. [24] have observed that among the 17 Hb
sites cleaved by the schistosome aspartyl proteases, 12 P1
residues and six P1P residues were either Leu or Phe. In addi-
tion, two out of the three initial cleavage sites had a Leu
residue either on P1 or P1P positions. Considering that this
markedly preference must be a result of a higher number of
favorable contacts between substrate moieties and the active
site residues atoms we have modelled two complexes between
the CatD_Sman model and the transition state analogues of
the peptides representing positions P4^P4P in the cleavage sites
KL105^L106 (SHCL*LVTL; Fig. 2B) and LL31^L32
(LGRL*LVVY) from K- and L-chains, respectively, of human
Hb. These substrates could be appropriately modelled from
the decapeptide renin inhibitor CH-66, which contains a Leu-
i[CHOHCH2]-Leu moiety, since a very tight superposition of
the CatD_Sman model and mouse renin could be achieved.
This procedure allowed us to de¢ne the enzyme residues cor-
responding to the subsite pockets S4^S4P (Schechter and Ber-
ger’s nomenclature [34]). For all of the subsites studied, with
exception of S2, several hydrogen bonds could be detected
between substrate backbone atoms and enzyme moieties (Ta-
ble 1). Nevertheless, not all hydrogen bonds predicted be-
tween the ON1 and ON2 atoms from the catalytic aspartates
and the P1-Leu carbonyl oxygen (as detected in the mouse
renin^CH-66 complex [22]) were detected in CatD_Sman
and its modelled substrates. This observation is probably ex-
plained by the existence of a slight di¡erence in the rotameric
position of the aspartate side chains in the crystallized mouse
renin structure in comparison to the CatD_Sman model.
Table 1
Hydrogen bonds between residues mapped in the S4^S4P subsites of the CatD_Sman model and the atoms of the substrates transition state
analogues
Enzyme residue and atom Substrate analogue Substrate analogue moiety Distance (Aî )
S223 OQ KL105^L106 His (P3) N 2.99
LL31^L32 Gly (P3) N 2.92
N KL105^L106 His (P3) O 2.90
LL31^L32 Gly (P3) O 2.80
T80 OQ1 KL105^L106 Cys (P2) N 2.62
LL31^L32 Arg (P2) N 2.49
N KL105^L106 Cys (P2) O 3.31
LL31^L32 Arg (P2) O 2.90
G79 N KL105^L106 Cys (P2) O 3.08
LL31^L32 Arg (P2) O 3.13
KL105^L106 Leu (P1P) O 3.31
LL31^L32 Leu (P1Q) O 3.31
D33 ON1 KL105^L106 Leu (P1) O 2.85
ON2 KL105^L106 Leu (P1) O 2.94
D219 ON2 LL31^L32 Leu (P1) O 2.38
G221 O KL105^L106 Leu (P1) N 3.10
LL31^L32 Leu (P1) N 3.07
G35 O KL105^L106 Val (P2P) N 2.68
LL31^L32 Val (P2P) N 2.73
H77 O LL31^L32 Val (P3P) N 3.27
K301 O LL31^L32 Tyr (P4P) OH 2.75
Table 2
Comparison between subsite composition of S. mansoni and human cathepsin D proteasesa
Subsite S. mansoni Human Subsite S. mansoni Human
S4 S223 S235 S4P K301 P314
M224 L236 R302 P313
M295 M307
L291 L303
S3 Q14 Q14 S3P H77 H77
T80 S80 R302 P313
F120 F131 L299 I311
F115 F126
S2 T222 T234 S2P G35 G35
A226 V238 S36 S36
L297 M309 H77 H77
I306 I320 I131 I142
I217 I229 Y194 Y205
S1 V31 V31 S1P Y78 Y78
D33 D33 G79 G79
Y78 Y78 Y194 Y205
G79 G79 I217 I229
I123 I134 D219 D231
G221 G233 L299 I317
aHighlighted in bold are residues mutated in S. mansoni protease in relation to cathepsin D. Detached in italic are the residues from CatD_S-
man not detected in the stipulated contact range of 4.0 Aî .
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The ¢rst step in validating a parasitic protease as a target
for chemotherapy should be the study on how to selectively
block its activity over the host orthologous enzyme. This can
be e¡ectively achieved by correlating the di¡erences found in
substrate preference of the parasitic and human proteases with
the structures in the active site of these enzymes. S. mansoni
aspartyl hemoglobinase shows only moderated similarity to
most human aspartyl proteases (including cathepsin E, renin
and pepsin). Nevertheless, it is signi¢cantly similar to the ly-
sosomal human enzyme cathepsin D (71% of similarity in 240
residues from the mature enzymes). Indeed it can be assumed
from the phenogram shown in Fig. 3 that CatD_Sman is
clearly closer to human cathepsin D than to any other host
protease. The tree shown in Fig. 3 was rooted with HIV-1
proteinase monomer sequence, since it would better represent
the ancestral gene that has given rise to the known eukaryotic
aspartyl proteases [35]. This close relationship between the
schistosome protease and human cathepsin D led us to focus
on the comparison between the residue composition and the
electrostatic properties on the surfaces of the subsite pockets
from these enzymes. In Table 2 are listed the residues occupy-
ing homologous positions in the S4^S4P subsites, according to
a structural superimposition of the human and schistosome
protease. Di¡erences were encountered in the residue compo-
sition as well as in the electrostatic properties on the surfaces
of the S4, S3, S2 and S3P pockets.
The S2 and S4 subsites are fundamentally formed by the
same molecular framework, where a clear distinction between
the individual pockets was di⁄cult to de¢ne. These pockets
are formed by the L-turn between the s6C and s7C L-strands
(spanning residues S223^G227, as de¢ned in Fig. 1) and by
the s12C strand (comprising residues C290^L297). Although a
similar analysis by Brinkworth et al. [25] has classi¢ed this
pocket as essentially hydrophobic, we found that this subsite
architecture results in a shallow and amphipathic S4 pocket,
which is similar to that described for human cathepsin D [21].
Mutation of L236 to M224 in the parasite enzyme provides a
hydrophobic environment which can result in a more favor-
ably interaction with a short hydrophobic side chain in oppo-
sition to the human enzyme. This could explain why a serine
can be found among the residues occupying the P4 position in
the sites cleaved in bovine Hb by the human cathepsin D [36]
while this amino acid never occurred in the same position of
human Hb sites cleaved by the schistosome enzyme. Impor-
tant discrepancies between the parasitic and human enzymes
could be encountered in the S2 subsite. In the human enzyme,
A226 is substituted for V238 in the loop between s6C and s7C
strands and L297 is substituted for M309 in the tip of the
s12C L-strand. The large diversity in the kind of side chain
favored in the large and hydrophobic S2 subsite of human
cathepsin D poses further di⁄culty in interpreting the struc-
ture^activity relationships of the same pocket in the schisto-
some enzyme. Gulnick et al. [37] have observed that the hu-
man enzyme more e¡ectively cleaves substrates having sulfur-
containing residues such as methionine or cysteine in the P2
position. However, Scaborough and Dunn [38] have shown
that the wild-type human enzyme bearing M287 (M309 ac-
cording to the numeration in Fig. 1) displays a preference for
hydrophobic residues such as Leu while moderately accom-
modating polar side chains such as Glu in the P2 position of
Fig. 4. Comparison between the electrostatic potential at the active site cleft surfaces of the CatD_Sman model (A) and the human cathepsin
D structure (B). Subsite pockets are indicated in each structure. The surface corresponding to the £ap and the second N-terminal helix are not
shown for a better visualization of the substrate binding groove.
Fig. 5. Superimposition of S3 residues of CatD_Sman (cyan) and
human cathepsin D (blue). Q14 assumes di¡erent conformations in
both enzymes. F115 (orange) in the parasitic enzyme is in a di¡erent
orientation from that of the correspondent F126 residue in the hu-
man protease.
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substrates. Thus, large hydrophobic (Met or Leu), medium
polar (cysteine) as well as large positively charged (Glu) res-
idues can ¢t the S2 pocket of human cathepsin D. According
to the mutations observed in the S2 pocket of the parasitic
enzyme we can only propose that this subsite being even larg-
er would favor the binding of large hydrophobic groups. In
addition, examining the surface of both enzymes, two major
di¡erences that can a¡ect S4 and S2 subsites are encountered
(Fig. 4). First, a protuberance in the C-terminal border is
clearly di¡erentiable in the human enzyme, which can re£ect
in less conformational freedom in the binding of the P4 and
P2 residues of the substrate. This di¡erence is caused by the
mutation of G247 for Q258 in the human enzyme. Second,
there is a considerable hydrophobic patch near the S4 pocket
surface in CatD_Sman that is absent from the human enzyme,
which may also favor the binding of hydrophobic residues in
this subsite. In the £ap position above the S3 subsite region,
S80 is mutated for T80 in the parasite enzyme. This change
seemed to have no major e¡ect on the hydrogen-bonding
pattern observed between the £ap and the substrate backbone.
Although much information can be obtained directly by
comparison of the primary sequence of the two enzymes, cer-
tain observations can only be made using 3D models. For
instance, as depicted in Fig. 5, residue Q14 in the S3 subsite,
in spite of being conserved, assumes di¡erent conformations
in both enzymes. According to our model, the rotamer for
Q14 in the parasitic protease has its side chain pointed outside
the pocket, while in the human enzyme it is directed toward
the binding cleft. This would enable bulkier side chains, such
as that of histidine in the KL105^L106 substrate, occupy the
S3 pocket (yellow in Fig. 5) where only a short side chain,
such as that of valine in the P3 position of the statin-based
inhibitor of human cathepsin D [21], would ¢t (green in Fig.
5). Indeed, carefully analysis of the cleavage sites in human
Hb suggests that residues with longer side chains, such as
arginine or glutamine, are preferred by the parasitic enzyme
in the P3 position. On the other hand, it has recently been
shown that the human enzyme attacks with greater e⁄ciency
£uorogenic substrates bearing the residues leucine, valine or
glutamic acid [39] in this position. We also detected that F115
(orange in Fig. 5) in the parasitic enzyme is in a di¡erent
orientation from that of the homologous F126 residue in
the human protease. This possibly accounts for the fact that
F115 was not initially detected in the set of residues within 4.0
Aî from substrate atoms. Other residues have been substituted
between the two enzymes in the loop connecting s7N and h2N
(F115^I123) making up the framework of the S3 pocket, as
noted before by Wong et al. [11], but none of these should
a¡ect interactions with P3 side chains of substrates.
None of the residues that are near to substrate atoms di¡ers
in S2P subsite of both schistosome and human proteases.
However, mutations in residues surrounding I131 in the
loop connecting the s8N strand and the h2N helix (S130 for
R141, D134 for N145 and G135 for N146) would turn the
pocket in the mammalian enzyme more hydrophilic than in
the parasitic homologue. It has been proposed before that the
hydrophobic S2P pocket in human enzyme can accommodate
polar or charged residues by enabling the polar group to point
out of the cleft and be stabilized by the solvent [40]. Indeed,
inspection of the residues favored in P2P position of protein
substrates cleaved by human cathepsin D characterizes a pref-
erence for short and polar residues.
A special feature of the structures of renin and cathepsin D
is the presence of a proline-rich loop (also referred to as the
Fig. 6. Comparison of the surfaces at the active site C-terminal boundaries in CatD_Sman model (A) and human cathepsin D structure (B).
A: The substrate analogue comprising KL105^L106 cleavage site of human Hb (SHCLi[CH(OH)CH2]LVTL; yellow) is shown superimposed
on the statin-based inhibitor of human cathepsin D (Iva-VV-Sta-i[CH(OH)CH2OH]GA-Sta; green [21]). B: Only the statin-based inhibitor is
shown docked at the human cathepsin D active site cleft. Iva = isovaline and Sta = statin.
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‘rigid loop’) connecting the s11C and s12C L-strands forming
the border of the S3P and S4P subsites. The equivalent struc-
ture in the CatD_Sman model is formed by a sequence of
three basic residues ^ K301, R302 and K303, for this reason
being hereafter referred to by us as the ‘basic loop’. The pro-
line-rich loop in human cathepsin D is displaced by 2.7 Aî
away from the center of the binding groove in relation to
the basic loop in CatD_Sman. An immediate consequence
of this di¡erence can be noted as a protuberance in the surface
of the CatD_Sman model, which would leave much less space
for accommodating large side chains in these pockets (Fig.
6A). A good example of how this can a¡ect the binding of
substrates/inhibitors can be found in the backbone torsion
within the statin-based inhibitor of human cathepsin D re-
sponsible for making P3P pointing toward S1P in the complex
[21]. Comparison of the surfaces of the complexes on the S3P
binding pockets of both enzymes (Fig. 6A,B) shows that it
would be impossible for an inhibitor of S. mansoni aspartyl
protease to su¡er this backbone torsion because of the steric
blockage that is imposed by the basic loop. The complex
between CatD_Sman and the modelled substrate (KL105^
L106 cleavage site of Hb) shows that the bulk Tyr side chain
in P3P would have to be torsioned out of the binding pocket in
order to be accommodated in S3P (Fig. 6A). Based on the
precedent discussion we propose that although larger side
chains can occupy P3P position in CatD_Sman substrates, a
favorable ¢t would only be achieved by short and polar res-
idues. Again, our conclusions disagree with the observations
made by Brinkworth et al. [25] that considered the S3P pocket
as markedly hydrophobic. Analysis of interactions within the
S4P pocket of CatD_Sman was made di⁄cult by the fact that:
(i) P4P in modelled substrates was positioned in the limit of
the active site N-terminal half or prime region (adopting the
nomenclature of Schechter and Berger [34]) and (ii) a direct
comparison with the human cathepsin D complexed inhibitor
was impossible in view of its particular binding mode as dis-
cussed before.
S1 and S1P subsite structures of both schistosome and hu-
man enzymes were very similar. They showed an almost per-
fect superimposition of the strands forming the i-like struc-
ture in the active site of several aspartyl proteinases and all of
the residues within 4.0 Aî from the atoms of the modelled
substrates were conserved between the two proteases. Never-
theless, several sites in human Hb K-chain are cleaved by the
schistosome enzyme but are not recognized by the human
protease, based on the orthologous sites in bovine Hb. Among
these sites, KPhe36^Pro37 deserves special attention because it
represents a very unusual primary speci¢city for an eukaryotic
aspartyl proteinase. Brinkworth et al. [25] have proposed that
a rationale for this would be that when Pro is at P1P the
backbone atom locations in P2, P1 and P1P are changed,
which in human cathepsin D would produce a destabilization
because of the lack of important hydrophobic contacts be-
tween Phe at P1 and residues in the S1 pocket. By careful
inspection of the models generated we have observed that
the substitution of Ala preceding D219 in CatD_Sman by
Val in the human protease would make the S1P pocket of
the later smaller and more hydrophobic. The larger S1P pocket
in CatD_Sman would collaborate to a better accommodation
of the rigid proline cycle at this position and thus help Phe at
P1 to ¢nd a more stable conformation in S1.
Cleavage sites bearing Phe^Pro at P1^P1P positions have
only been e⁄ciently hydrolyzed by retroviral aspartyl protein-
ases [41] and it has been suggested that the selectivity evi-
denced by HIV-1 protease is the consequence of an extensive
network of interactions, not only within the S4^S3P subsites,
but also extending beyond this segment [41]. This pattern
would indicate that only a more rigorous and systematical
study involving substitutions in P4^P4P positions of synthetic
substrates will be able to identify any subtle di¡erences exis-
tent in S1^S1P subsites from the schistosome and human pro-
teases. The exclusive speci¢city of retroviral aspartyl protein-
ases has been extensively explored, as it became the ¢rst
approach to reach selectivity within the anti-HIV-1 drugs
[40]. Although successful in ¢nding selective peptidic leads,
this approach has fallen short in designing e¡ective drugs
mainly because of the low bioavailability of the designed pep-
tidomimetics compounds [41]. The two compounds designed
following this concept that have reached the market are the
Ho¡mann-La Roche RO318959 (Saquinavir) and the Merck
L-735,524 (Indinavir). Most recent approaches that have tak-
en full advantage on the 3D structure of the HIV-1 protease
have been more productive in ¢nding anti-viral drugs [41,42].
At this time three drugs were successfully designed in this
way: the Vertex VX478 (Amprenavir), the Agouron AG-
1343 (Nel¢navir) and the Pharmacia-Upjohn PNU-140690
(Tipranavir). The approach followed in this work, in which
the general topological and chemical features responsible for
substrate recognition by the schistosome and human ortholo-
gous enzyme were compared, would facilitate this type of drug
design strategy.
The abnormal similarity with the HIV-1 protease can be
explored in the design of inhibitors of the schistosome aspar-
tyl hemoglobinase through the in vitro or in silico screening of
known HIV-1 protease inhibitors. Nevertheless, besides the
a⁄nity for substrates bearing a hydrophobic Pro motif as
P1^P1P residues, a number of studies have pointed out the
essentially hydrophobic S2 and S2P subsites as the most crit-
ical in de¢ning e¡ective substrate interactions with the HIV-1
protease [43]. Thus, many substrate-based HIV-1 protease in-
hibitors re£ect these requirements [44]. For example, the cis-
decahydroisoqinoline moiety found in Saquinavir and Nel¢-
navir mimics the proline at P1P as well as it provides some
interactions at the S3P binding site, while the bulky t-butyla-
mide ¢lls S2P. The general hydrophilic character of its S2P
binding pocket would lower the binding a⁄nity of such in-
hibitors to the schistosome enzyme but it would also enhance
the selectivity for the parasitic enzyme over human cathepsin
D, since this subsite in the human orthologue tends to be even
more hydrophilic. As discussed above, S2 subsites on both the
parasitic and human enzymes are hydrophobic. However, this
pocket seems to be narrower in the schistosome protease,
which would favor HIV-1 protease inhibitors with shorter
P2 groups.
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